Dr. Sellam Karunanithi is a nuclear medicine physician specializing in advanced molecular imaging and radionuclide therapy for cancer, neurological disorders, and cardiovascular diseases. His clinical expertise focuses on the use of nuclear medicine techniques that combine diagnostic imaging and targeted therapy to detect diseases at early stages and guide precision treatment.
He has extensive experience in PET-CT imaging for oncology, neurology, and cardiology, which plays a critical role in detecting cancers, evaluating tumor spread, and monitoring treatment response. PET-CT imaging is widely used for accurate staging of malignancies and for guiding treatment decisions in oncology.
Dr. Karunanithi also performs nuclear cardiology procedures such as myocardial perfusion imaging and myocardial viability studies, which help evaluate blood flow to the heart muscle and assess coronary artery disease.
His expertise includes targeted radionuclide therapies such as radioiodine therapy (I-131) for thyroid cancer and Graves’ disease, as well as advanced therapies like Lu-177 DOTATATE and PSMA therapy for neuroendocrine tumors and prostate cancer.
Through modern molecular imaging technologies and radionuclide treatments, he focuses on improving diagnostic accuracy and delivering personalized treatment strategies for patients with complex medical conditions.
Dr. Sellam Karunanithi specializes in PET-CT imaging used for diagnosing and staging cancers, neurological disorders, and cardiac diseases.
Yes. Dr. Sellam Karunanithi performs radioiodine (I-131) therapy for thyroid cancer, Graves’ disease, and toxic nodular goiter using nuclear medicine techniques.
He performs targeted radionuclide therapies such as Lu-177 DOTATATE and PSMA therapy used in the treatment of neuroendocrine tumors and prostate cancer.
Dr. Sellam Karunanithi performs myocardial perfusion imaging and myocardial viability studies to evaluate heart muscle function and coronary artery disease.
